Beyond Blood Sugar: Ele Ferrannini on the Basis for the Transformative Power of SGLT2 Inhibitors for Kidney Disease Management at WCN’24
Ele Ferrannini, a professor of Internal Medicine at the University of Pisa and a senior research associate at the National Research Council Institute of Clinical Physiology, will present the plenary talk “Insights Into SGLT2 Inhibitors: A Story of Discovery” at WCN’24 in Hall A on Tuesday, April 16 at 11 a.m. Argentina time.
Register for the congress now to benefit from the early bird rate!
Sodium-glucose cotransporter 2 (SGLT2) inhibitors are a class of drugs initially developed for glycemic control in diabetes mellitus. They reduce elevated blood glucose levels by inhibiting glucose reabsorption in the kidneys and promoting its excretion through the urine.
SGLT2 inhibitors have garnered significant attention due to their unexpectedly beneficial impact on multiple organ systems. Beyond glucose regulation, these inhibitors have demonstrated notable cardiovascular benefits, especially heart failure, and can significantly help reduce the risk of kidney-related complications.
By inhibiting glucose reabsorption in the kidneys, these drugs set in motion a cascade of hemodynamic and metabolic mechanisms, eventually reducing the workload on renal cells and lowering inflammation and oxidative stress.
With kidney diseases on the rise worldwide, innovative therapies such as SGLT2 inhibitors are set to play a key role in the evolving landscape of chronic disease management, holding the potential to treat people with kidney and other non-communicable diseases effectively.
Find out more about WCN’s plenary speakers and scientific program here.
